Stock 600739 LIAONING CHENG DA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Liaoning Cheng Da Co., Ltd.

Equities

600739

CNE000000LY3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 07/05/2024 BST 		5-day change 1st Jan Change
10.3 CNY -1.15% Intraday chart for Liaoning Cheng Da Co., Ltd. -0.68% -12.56%
04-29 Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-26 Liaoning Cheng Da Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 16,001 23,297 37,203 29,860 19,194 17,933
Enterprise Value (EV) 1 25,721 32,705 46,047 35,430 24,554 23,662
P/E ratio 21 x 19.4 x 13.4 x 13.8 x 15.7 x 77 x
Yield - 0.66% 0.9% 1.13% 1.19% -
Capitalization / Revenue 0.83 x 1.31 x 2.2 x 1.63 x 1.32 x 1.66 x
EV / Revenue 1.33 x 1.84 x 2.72 x 1.93 x 1.69 x 2.19 x
EV / EBITDA 25.6 x 31.2 x 57.4 x 22.8 x 15.6 x 26.3 x
EV / FCF -31.8 x 102 x -18.3 x -11.5 x 373 x 22 x
FCF Yield -3.15% 0.98% -5.45% -8.71% 0.27% 4.55%
Price to Book 0.79 x 1.08 x 1.55 x 1.07 x 0.67 x 0.62 x
Nbr of stocks (in thousands) 1,529,710 1,529,710 1,529,710 1,529,710 1,524,577 1,522,316
Reference price 2 10.46 15.23 24.32 19.52 12.59 11.78
Announcement Date 28/04/19 02/04/20 28/04/21 21/04/22 14/04/23 26/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 19,275 17,746 16,945 18,373 14,565 10,783
EBITDA 1 1,005 1,049 802.9 1,556 1,571 900.7
EBIT 1 694.6 686 426 1,192 1,199 553.6
Operating Margin 3.6% 3.87% 2.51% 6.49% 8.24% 5.13%
Earnings before Tax (EBT) 1 982.9 1,486 2,699 2,634 1,715 109.3
Net income 1 761.8 1,202 2,771 2,159 1,224 233.1
Net margin 3.95% 6.77% 16.35% 11.75% 8.4% 2.16%
EPS 2 0.4980 0.7857 1.812 1.412 0.8010 0.1530
Free Cash Flow 1 -809.9 320.6 -2,511 -3,088 65.89 1,077
FCF margin -4.2% 1.81% -14.82% -16.81% 0.45% 9.99%
FCF Conversion (EBITDA) - 30.57% - - 4.2% 119.63%
FCF Conversion (Net income) - 26.68% - - 5.39% 462.26%
Dividend per Share - 0.1000 0.2200 0.2200 0.1502 -
Announcement Date 28/04/19 02/04/20 28/04/21 21/04/22 14/04/23 26/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 9,720 9,408 8,845 5,570 5,359 5,729
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 9.676 x 8.97 x 11.02 x 3.58 x 3.412 x 6.361 x
Free Cash Flow 1 -810 321 -2,511 -3,088 65.9 1,077
ROE (net income / shareholders' equity) 3.98% 5.97% 10.5% 8.81% 4.57% -0.04%
ROA (Net income/ Total Assets) 1.22% 1.14% 0.68% 1.71% 1.56% 0.73%
Assets 1 62,547 105,196 407,960 126,283 78,483 32,012
Book Value Per Share 2 13.30 14.10 15.70 18.30 18.80 18.90
Cash Flow per Share 2 1.570 1.390 1.390 3.660 5.680 3.890
Capex 1 500 760 330 614 647 703
Capex / Sales 2.6% 4.28% 1.95% 3.34% 4.44% 6.52%
Announcement Date 28/04/19 02/04/20 28/04/21 21/04/22 14/04/23 26/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
LIAONING CHENG DA CO., LTD. Stock Liaoning Cheng Da Co., Ltd.
-12.56% 2.2B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.95% 700B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 569B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.97% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.83% 330B
ABBVIE INC. Stock AbbVie Inc.
+3.54% 287B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.70% 236B
NOVARTIS AG Stock Novartis AG
+6.68% 202B
ROCHE HOLDING AG Stock Roche Holding AG
-9.08% 197B
AMGEN INC. Stock Amgen Inc.
+6.70% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600739 Stock
  4. Financials Liaoning Cheng Da Co., Ltd.